BIOATLA, INC. (BCAB) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-23.48M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -0.27× | Operating cash flow / net income. Period ending 2026-06-30. $-23.48M ÷ $87.75M ≈ -0.27× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -23.48M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 87.75M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-23.48M | (m) | (m) | (m) | (m) | $87.75M | (m) | (m) | (m) | -0.27× |
| 2026-03-31 | (m) | (m) | $-37.18M | (m) | (m) | (m) | (m) | $-50.62M | (m) | (m) | (m) | 0.73× |
| 2025-12-31 | (m) | (m) | $-48.20M | (m) | (m) | (m) | (m) | $-59.61M | (m) | (m) | (m) | 0.81× |
| 2025-09-30 | (m) | (m) | $-57.07M | (m) | (m) | (m) | (m) | $-64.71M | (m) | (m) | (m) | 0.88× |
| 2025-06-30 | (m) | (m) | $-52.32M | (m) | (m) | (m) | (m) | $-59.52M | (m) | (m) | (m) | 0.88× |
| 2025-03-31 | (m) | (m) | $-57.40M | (m) | (m) | (m) | (m) | $-61.88M | (m) | (m) | (m) | 0.93× |
| 2024-12-31 | (m) | (m) | $-71.94M | (m) | (m) | (m) | (m) | $-69.78M | (m) | (m) | (m) | 1.03× |
| 2024-09-30 | (m) | (m) | $-85.08M | (m) | (m) | (m) | (m) | $-81.82M | (m) | (m) | (m) | 1.04× |
| 2024-06-30 | (m) | (m) | $-107.29M | (m) | (m) | (m) | (m) | $-104.56M | (m) | (m) | (m) | 1.03× |
| 2024-03-31 | (m) | (m) | $-112.19M | (m) | (m) | (m) | (m) | $-119.24M | (m) | (m) | (m) | 0.94× |
| 2023-12-31 | (m) | (m) | $-104.02M | (m) | (m) | (m) | (m) | $-123.46M | (m) | (m) | (m) | 0.84× |
| 2023-09-30 | (m) | (m) | $-98.44M | (m) | (m) | (m) | (m) | $-124.08M | (m) | (m) | (m) | 0.79× |
| 2023-06-30 | (m) | (m) | $-95.11M | (m) | (m) | (m) | (m) | $-116.53M | (m) | (m) | (m) | 0.82× |
| 2023-03-31 | (m) | (m) | $-87.94M | (m) | (m) | (m) | (m) | $-109.69M | (m) | (m) | (m) | 0.80× |
| 2022-12-31 | (m) | (m) | $-90.42M | (m) | (m) | (m) | (m) | $-106.48M | (m) | (m) | (m) | 0.85× |
| 2022-09-30 | (m) | (m) | $-87.02M | (m) | (m) | $0.00 | (m) | $-102.33M | (m) | (m) | (m) | 0.85× |
| 2022-06-30 | (m) | (m) | $-75.73M | (m) | (m) | $0.00 | (m) | $-99.48M | (m) | (m) | (m) | 0.76× |
| 2022-03-31 | (m) | (m) | $-72.36M | (m) | (m) | (m) | (m) | $-100.95M | (m) | (m) | (m) | 0.72× |
| 2021-12-31 | (m) | (m) | $-62.21M | (m) | (m) | $300.00K | (m) | $-95.40M | (m) | (m) | (m) | 0.65× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $-36.33M | (m) | (m) | (m) | (m) | $-35.85M | (m) | (m) | (m) | 1.01× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $-9.64M | (m) | (m) | (m) | (m) | $-29.86M | (m) | (m) | (m) | 0.32× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |